AstraZeneca to invest $300m in new cell therapy production facility in US
AstraZeneca said the investment in the new manufacturing facility in Rockville, Maryland, will advance the discovery and development…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Feb 24
AstraZeneca said the investment in the new manufacturing facility in Rockville, Maryland, will advance the discovery and development…
07 Feb 24
Under the expanded collaboration, both firms will further explore Calibr-Skaggs’ switchable CAR-T platform to develop cell therapy candidates…
07 Feb 24
The Phase 2, multi-centre, randomised, double-masked, parallel group study will assess the efficacy and safety of KHK4951 in…
06 Feb 24
Novo Nordisk has agreed to acquire Catalent’s three fill-finish sites located in Anagni, Italy; Brussels, Belgium; and Bloomington,…
06 Feb 24
Myalepta is indicated as a replacement therapy as an adjunct to diet to treat the complications of leptin…
06 Feb 24
Under the partnership, both firms will start a research and development collaboration at AstraZeneca’s Innovation Campus (iCampus) in…
06 Feb 24
The collaboration, includes MGI's first corporate order of the revolutionary DNBSEQ-T20×2 ("T20") ultra-high throughput sequencer in the Middle…
05 Feb 24
Genmab and Pfizer’s marketing authorisation application (MAA) for Tisotumab vedotin, an antibody-drug conjugate (ADC) intended for the treatment…
05 Feb 24
The approval was based on the positive outcomes of the ReSTORE Phase 3 clinical trial in which rezafungin…
05 Feb 24
Inmagene has obtained an exclusive, worldwide and royalty-bearing license for the two drug candidates to further develop, manufacture…